
zzso an zzso and zzso drug, and zzso an zzso zzso have synergistic zzso effects in zzso zzso We conducted a phase I study of the combination in patients with advanced zzso 

A zzso + zzso study design was zzso During the escalation phase, zzso zzso days zzso and zzso zzso once a week) were given at the following respective zzso level 1 (10 zzso 15 zzso level 2 (10 zzso 20 zzso level 3 (20 zzso 20 zzso and level 4 (20 zzso 25 zzso (1 cycle zzso 28 zzso The maximum tolerated dose, zzso zzso and response were zzso 

zzso patients were treated zzso age: 58 years zzso zzso zzso zzso The most common diagnoses were zzso cancer (N zzso zzso zzso (N zzso zzso neuroendocrine zzso (N zzso 4) and zzso zzso zzso (N zzso zzso Overall, 121 cycles zzso 2) were zzso No zzso zzso were zzso The maximum tested dose zzso level 4) was used in the expansion zzso Grade zzso zzso zzso zzso (all zzso were seen in 19 zzso patients and included zzso (N zzso zzso zzso (N zzso zzso and infection (N zzso zzso Grade 3 zzso and Grade 3 zzso were noted in zzso and zzso of patients, zzso Of 43 patients, 30 zzso received zzso zzso There were no zzso zzso Response was zzso in 40 zzso one zzso patient had a partial response and 19 zzso had stable disease zzso with zzso zzso 6 months in 6 zzso zzso zzso types with zzso zzso 6 months were soft tissue zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso and neuroendocrine zzso zzso zzso The median zzso survival duration was zzso months zzso zzso zzso and the median overall survival duration was zzso months zzso zzso zzso 

zzso and zzso combination therapy was well tolerated and associated with clinical benefit in patients with soft tissue zzso zzso zzso zzso neuroendocrine zzso zzso zzso and zzso zzso 

